### **Overview** Bal Pharma Limited is a **fully integrated pharmaceutical company** with over **35 years of operational history**, specializing in the development, manufacturing, and marketing of **Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), generics, pharmaceutical intermediates, and herbal/AYUSH-based medicines**. Headquartered in India, the company operates across **three core business segments**: API (57%), formulations (43%), and Ayurveda (1%). It has a **strong domestic and international presence**, exporting to **over 80 countries**, including regulated markets (EU, US, Japan, Australia, Canada) and semi-regulated regions (Africa, Latin America, Middle East, CIS). Bal Pharma is recognized as **one of the largest producers and exporters of Gliclazide**, a key anti-diabetic drug used in type-2 diabetes treatment. --- ### **Leadership & Governance** - **Mr. Shailesh D Siroya**: Chief Promoter & Managing Director; over 29 years of industry experience. - **Mr. Himesh Virupakshaya**: Executive Director; chemical engineer with over 33 years of expertise in API manufacturing. --- ### **Business Segments & Therapeutic Focus** Bal Pharma operates through multiple business divisions with distinct brand architectures and focused market strategies: | **Division** | **Focus** | **Key Brands** | **Market Reach** | |------------|----------|----------------|------------------| | **Vibrant** | Multispecialty (nutritional, anti-allergic, anti-fungal, gastro, gynecology) | EBAL, Aziwin, Secremet | Pan-India with 246+ field reps, 2,800+ stockists, 41,300+ doctors | | **Glyduz / Servetus** | Diabetes & Cardiology | Diabend, Glyduz, SITABEND, SITABEND-M | 8 Indian states; 127+ field staff, 338+ stockists | | **Institutional Sales** | Government & hospital supply | Various generics | PSU, Railways, State/Central Govt. contracts via rate tenders | | **Lifezen** | OTC & Consumer Health | Lifezen brand portfolio | Domestic and export-focused; dedicated to building sustainable brands | | **Bal Vedics** | Integrated herbal remedies | Stonex (kidney stones), Ashwamed (male infertility), Prostowin (prostate), Ayursulin (diabetes) | Domestic market focus; growing traction with dedicated team | **Therapeutic Areas Across Portfolio**: > Anti-diabetes, Cardiology, Gastroenterology, Dermatology, Neuropsychiatry, Pain Management, Gynecology, Ophthalmology, Anti-infectives, Anti-inflammatory, Anti-histamine, Oncology (historically emphasized), Erectile Dysfunction, and Anti-protozoals. --- ### **Manufacturing & Operations** Bal Pharma operates **six state-of-the-art manufacturing facilities** located across: - Bangalore (Karnataka) - Rudrapur (Uttarakhand) - Sangli (Maharashtra) - Pune (Maharashtra) - Udaipur (Rajasthan) - Kadechur (Karnataka) – *Under development* #### **Key Facilities & Capabilities** - **Bangalore**: FDF plant (1992), API multi-purpose unit (1996) with **in-house R&D center** (government-approved). - **Rudrapur**: Excise-free zone, WHO-GMP compliant API facility for regulated markets. - **Sangli**: Intermediates manufacturing, supporting Bangalore’s API production. - **Pune**: Parenteral manufacturing (SVP & LVP) using Form-Fill-Seal tech (WHO-GMP). - **Udaipur**: Undergoing regulatory upgrades for compliance with EU and US standards. - **Kadechur (Karnataka)**: New bulk drug plant under development (see Expansion). #### **Production Capacity** - **APIs**: 370 tonnes/year across **22+ molecules** - **FDFs**: 3 billion tablets, 490 million capsules, 10 million cream units annually - **Global Regulatory Approvals**: Holds **over 300 approvals**, including: - **EDQM (COS)**, **TGA Australia**, **PMDA Japan**, **MOH Canada**, **KFDA Korea** - **EU GMP (Malta)**, **NAFDAC (Nigeria)**, **TFDA (Tanzania)**, **PPB (Kenya)**, **MCAZ (Zimbabwe)** --- ### **Research & Development** - In-house R&D center in Bangalore focused on **process development, formulation innovation, and regulatory dossier preparation**. - Strong product pipeline: - **API pipeline value**: ₹3,370 million - **Formulations pipeline value**: ₹270 million - Recent developments: - Pilot-scale production of **muscle spasm drug** (e.g., baclofen analogues) - Development of an **anti-anemia molecule** - Process optimization for **overactive bladder treatment** --- ### **Production Linked Incentive (PLI) Scheme – Strategic Enabler** Bal Pharma is a **qualified beneficiary** under the Indian government’s **PLI Scheme for APIs** (Category C for MSMEs). Key impacts: - Expected **average annual revenue boost of ₹1,250 million** over 5–6 years - Incentives estimated at **₹50 crore over the medium term** - Reinforces **domestic manufacturing scale, cost competitiveness, and profitability** - Claim submitted for FY2022–23, validating manufacturing scale and investment --- ### **Geographic Expansion & Sales Network** #### **Exports & Global Reach** - **API exports**: 63 countries; 58% of API revenue from exports - **FDF exports**: 34 countries - **Overall presence**: >80 countries including UK, Australia, EU, Africa, Latin America, Middle East, Southeast Asia - **Top Customers**: Contribute **60% of total revenue** - **Key Partnerships**: Supplying APIs to **Teva, Actavis, Krka, Apotex, Mylan, Takeda, Novartis, Sun Pharma, Dr. Reddy’s** #### **Revenue Mix (Geographic)** | Segment | Domestic | Regulated Markets | Semi-Regulated Markets | |--------|--------|-------------------|------------------------| | **API Revenue** | 33% | 14% | 53% | | **FDF Revenue** | 30% | — | 70% | #### **Recent Geographic Expansion (2023)** Entered new markets: **Uzbekistan, Guatemala, Malta** Near-term focus: **Expansion into African markets** --- ### **Growth Initiatives & Strategic Developments** #### ✅ **New Manufacturing Facility – Kadechur, Karnataka** - **Investment**: ₹36 crore - **Purpose**: New bulk drug manufacturing unit - **Status**: Single-window clearance received - **Timeline**: Expected completion within **4 years** - **Benefit**: Will de-load Bommasandra plant; serve domestic & international markets #### ✅ **Backward Integration for Supply Chain Security** - Achieved **in-house production of critical nitro-based intermediate** used in Gliclazide synthesis - Previously dependent on Chinese suppliers – now enhances **supply chain resilience, cost control, and strategic autonomy** #### ✅ **Regulatory Upgrades** - **Udaipur API facility**: Upgrading to meet international regulatory standards (EU, USFDA readiness) - EU-COS approvals secured for **Gliclazide, Ebastine, Adapalene** #### ✅ **Product Launches & Portfolio Strengthening** - Launched **Sitagliptin-based combinations (SITABEND & SITABEND-M)** post-patent expiry, strengthening diabetes portfolio - Added **16 new formulations** in FY23 - Expanded API customer base by adding **12 new global customers** #### ✅ **Human Capital & Marketing Strengthening** - Employs **over 1,000 people** - Actively hiring **experienced professionals** in marketing, R&D, and production - Over **400 medical representatives** targeting domestic FDF market share expansion - Increased **capital expenditure** on offices and manufacturing units --- ### **Financial Highlights (FY2022–FY2023)** - **API Segment**: - Q2 FY23 revenue: ₹2,371.84 million (49.83% of total) - API exports grew 11.65% YoY to ₹2,258.16 million - **Order book**: ₹2,450 million (Q2 FY23) - **Revenue Mix Shift**: - Q1 FY22: API contributed 63% → Q1 FY23: 44% - Indicates diversification into higher-margin formulations and branded domestic products --- ### **Challenges Addressed** - **Cash Flow Constraints** (2020): Mitigated long government payment cycles (up to 240 days) by **strategically reducing institutional supply exposure** - **China Dependence**: Addressed via **backward integration** into key intermediates, reducing import risk --- ### **Subsidiaries** 1. **Lifezen Healthcare Private Limited** 2. **Balance Clinics LLP** 3. **Bal Research Foundation** 4. **Golden Drugs Private Limited**